NCT06798831 - Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults | Biotech Hunter

Enrollment

2,399

Participants

Timeline

Start Date

February 8, 2025

Primary Completion Date

April 4, 2025

Study Completion Date

October 31, 2025

Conditions

Pertussis Vaccine

Interventions

BIOLOGICAL

Pertussis containing vaccine

Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),

Trial Locations (3)

Chula Clinical Research Center (Chula CRC), Bangkok

Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok

Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok

All Listed Sponsors

lead

BioNet-Asia Co., Ltd.

INDUSTRY